SK Biopharma和Full Life签署5.715亿美元的创新放射性药物FL-091协议-动脉网

SK Biopharma and Full-Life Sign US$571.5 Million Deal for Innovative Radiopharmaceutical FL-091

GeneOnline 等信源发布 2024-07-18 16:35



可切换为仅中文







by Denisse Sandoval

Denisse Sandoval

Share To

共享给

On July 17, SK Biopharmaceuticals Co., Ltd. announced its joint license agreement worth US$571.5 million with Full-Life Technologies Limited (Full-Life).The agreement grants SK Bio exclusive worldwide rights for clinical research, manufacturing, development, and commercialization of Full-Life’s radiopharmaceutical compound, FL-091, a novel agent targeting neurotensin receptor 1 (NTSR1)-positive cancers.FL-091 Targeting Solid Tumors Overexpressing the NTSR1 Receptor for Enhanced Anti-Cancer TherapyFull-Life’s compound, FL-091, is a small-molecule radioligand designed to target NTSR1-positive solid tumors.

7月17日，SK生物制药有限公司宣布与Full Life Technologies Limited（Full Life）签订价值5.715亿美元的联合许可协议。该协议授予SK Bio对Full Life放射性药物化合物FL-091（一种靶向神经降压素受体1（NTSR1）阳性癌症的新型药物）的临床研究，制造，开发和商业化的全球独家权利。FL-091靶向过表达NTSR1受体的实体瘤以增强抗癌治疗Full Life的化合物FL-091是一种小分子放射性配体，旨在靶向NTSR1阳性实体瘤。

Specific cancer tumors overexpress the NTSR1 receptor protein, linking them to the progression of several cancers, including breast and pancreatic cancer. In preclinical studies, FL-091 radioligands demonstrated promising biodistribution profiles, improved binding affinity to NTSR1, and effective anti-tumor activity. Under the terms of the agreement, SK Biopharmaceuticals will acquire the NTSR1-targeting Radionuclide Drug Conjugate (RDC) program FL-091, as well as its backup compounds.

特定的癌症肿瘤过度表达NTSR1受体蛋白，将其与几种癌症（包括乳腺癌和胰腺癌）的进展联系起来。在临床前研究中，FL-091放射性配体表现出有希望的生物分布特征，对NTSR1的结合亲和力提高以及有效的抗肿瘤活性。根据协议条款，SK Biopharmaceuticals将收购NTSR1靶向放射性核素药物偶联物（RDC）计划FL-091及其备用化合物。

The company aims to develop and commercialize these compounds as innovative anti-cancer treatments. Additionally, SK Biopharma will secure a right of first negotiation for other selected RDC programs from Full-Life. CEO of Full-Life, Lanny Sun, stated, “This agreement with SK Biopharmaceuticals highlights the potential of FL-091 in advancing cancer treatment and demonstrates SK Biopharmaceuticals’ unwavering commitment to building an oncology business around medical innovation.

该公司旨在开发和商业化这些化合物作为创新的抗癌治疗方法。此外，SK Biopharma将获得其他选定RDC计划的首次谈判权。Full Life首席执行官Lanny Sun表示：“与SK Biopharmaceuticals的这项协议突显了FL-091在推进癌症治疗方面的潜力，并表明SK Biopharmaceuticals坚定不移地致力于围绕医疗创新建立肿瘤学业务。

”License Agreement Will Push SK Biopharmaceutical Towards Global Biotech LeadershipSK Biopharmaceuticals and Full-Life agreed on a licensing deal valued at US$571.5 million. This deal includes upfront payments and .

“许可协议将推动SK Biopharmaceutical走向全球生物技术领导者SK Biopharmaceuticals and Full Life就价值5.715亿美元的许可协议达成一致。这笔交易包括预付款和。

Rising Bird Flu Cases in Cattle and Humans Drive Global Efforts in Vaccination, Genetic Monitoring, and SurveillanceWistar and Accelerated Biosciences Partner to Develop Novel hTSCs Platform for Immunotherapies

牛和人类禽流感病例的增加推动了全球在疫苗接种、基因监测和监测方面的努力Wistar和Accelerated Biosciences合作伙伴开发新型hTSCs免疫治疗平台

Author

作者

Denisse Sandoval

Denise Sandoval